Search Results

L7 CEO Vasu Rangadass, Ph.D., argues that regulated process industries have reached the limits of point-solution modernization and must pivot to unified orchestration to unlock the promise of agentic AI.

Protect Clinical Assets. Preserve Enterprise Value. ClinPro Trials™ today announced the availability of its Independent Executive Compliance Intelligence™ service for investors seeking objective visibility into clinical trial compliance, inspection readiness and regulatory exposure across their clinical investment portfolios. As The Compliance CRO™, ClinPro Trials provides independent executive assessments designed to help protect clinical assets and preserve enterprise value. Every investor expects scientific risk. Few expect compliance failure. Fewer expect to discover it after years of investment and hundreds of millions of dollars—during a pre-approval inspection. A pre-approval inspection often reveals compliance deficiencies that could have been identified much earlier. Not because the science failed. But because compliance drifted during trial execution. Every milestone appeared to have been achieved. Every executive update suggested progress. But one critical question remained unanswered: Do we truly understand the compliance risk, inspection readiness and regulatory exposure of the clinical asset we are funding? ClinPro Trials™ was established to answer that question.

New GPU-powered system reduces whole-genome processing time from hours to minutes, unlocking population-scale genetic discovery and accelerating rare disease drug development